Fluciclatide F-18

Drug Profile

Fluciclatide F-18

Alternative Names: [18F]AH111585; AH111585-18F

Latest Information Update: 10 Mar 2016

Price : $50

At a glance

  • Originator GE Healthcare
  • Developer GE Healthcare; National Cancer Institute (USA)
  • Class Imaging agents; Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 27 Feb 2016 Asan Medical Center terminates phase II trial in Solid tumours (Diagnosis) in South Korea (NCT01961583)
  • 01 Oct 2015 No recent reports of development identified - Phase-II for Solid tumours (Diagnosis) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top